Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date

3152 results found

2024 ∙ Feng, S. McLellan, J. Pidduck, N. Roberts, N. Higgins, J. P. Choi, Y. Izu, A. Jit, M. Madhi, S. A. Mulholland, K. Pollard, A. J. Procter, S. Temple, B. Voysey, M.

Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Ouyang, L. Lei, G. Gong, Y.

Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Kavikondala, S. Haeussler, K. Wang, X. Spellman, A. Bausch-Jurken, M. T. Sharma, P. Amiri, M. Krivelyova, A. Vats, S. Nassim, M. Kumar, N. Van de Velde, N.

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Losa, L. Antonazzo, I. C. Di Martino, G. Mazzaglia, G. Tafuri, S. Mantovani, L. G. Ferrara, P.

Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression

  • All age groups
  • Herpes zoster
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Moderate
2024 ∙ Chenchula, S. Chandra, M. B. Adusumilli, M. B. Ghanta, S. N. Bommasani, A. Kuttiappan, A. Padmavathi, R. Amerneni, K. C. Chikatipalli, R. Ghanta, M. K. Reddy, S. S. Mythili Bai, K. Prakash, S. Jogender, G. Chavan, M. Balakrishnan, S.

Immunogenicity, clinical efficacy and safety of additional second COVID-19 booster vaccines against Omicron and its subvariants: A systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Administration
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Chirasuthat, S. Ratanapokasatit, Y. Thadanipon, K. Chanprapaph, K.

Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2024 ∙ Sharifi Aliabadi, L. Azari, M. Taherian, M. R. Barkhordar, M. Abbas, S. A. M. Azari, M. Ahmadvand, M. Salehi, Z. Rouzbahani, S. Vaezi, M.

Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2024 ∙ Vojtek, I. van Wouw, M. Thomson, A.

Impact of COVID-19 on vaccine confidence and uptake: A systematic literature review

  • All age groups
  • Acceptance
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2024 ∙ Muharam, R. Ika Putri, Y. Fitriayu Andyra, A. Ezekia, K. Elya Charilda, F. Bagastoro, A. Abigail Faradina, A. Pratama, G. Kemal Harzif, A.

Impact of COVID-19 Vaccination on In Vitro Fertilization Outcomes: A Systematic Review

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Kanan, M. Alotaibi, N. Alshehri, R. Alhoqail, A. Abdulazim, K.

Impact of human papillomavirus (HPV) prophylactic vaccination on infertile male patients with HPV semen infection: A systematic review

  • Adults
  • Human papillomavirus (HPV)
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...